Journal News

JLR: What controls cholesterol biosynthesis?

Laurel Oldach
September 01, 2019

Homeostasis is an important biochemical principle. The pace of a biosynthetic pathway often is controlled by feedback from pathway products, adjusting the system to prevent excessive accumulation of its products.

Pathway diagramA pathway diagram shows two parallel routes from mevalonate to cholesterol.Bao-Liang Song

Cholesterol biosynthesis is one example. Researchers know it is regulated by metabolic intermediates but until now have disagreed about which intermediates do the work. In the Journal of Lipid Research, Liang Chen and colleagues at Wuhan University and the Chinese Academy of Sciences report that several metabolites can affect the activity of two cholesterol biosynthesis enzymes. The study gives new insight into how cholesterol biosynthesis is regulated.

Researchers knew that an intermediate product of the biosynthetic pathway could inhibit each of two control points: HMG-CoA reductase, or HMGCR, which synthesizes a key cholesterol precursor called mevalonate, and sterol responsive element-binding protein, or SREBP, a transcription factor that affects many cholesterol synthesis enzymes.

Data suggested that lanosterol, the first intermediate in the pathway that is cyclic instead of linear, was the key regulator, but the researchers knew that a slightly modified version of lanosterol might be more important. The question is complicated because the cholesterol biosynthesis pathway bifurcates after lanosterol is formed.

In lanosterol or any of its downstream products, a double bond in the molecule’s alkyl tail can be reduced, and the reduced molecules proceed through the same steps to be turned into cholesterol (see figure). So which intermediate cholesterol metabolite exerts the most control over the overall biosynthetic pathway?

That is a technically difficult problem. It is hard to induce accumulation of specific intermediates, because no effective enzyme inhibitors exist for specific steps in sterol synthesis and cells are unlikely to take up exogenously added pathway intermediates.

Chen and colleagues worked around these difficulties by generating a cell line better equipped to absorb mevalonate, a key intermediate produced by HMGCR. In these cells, intermediates can accumulate even if HMGCR activity is blocked. When these cells are provided with mevalonate, they scale up cholesterol production, triggering homeostatic degradation of HMGCR and blocks SREBP activation.

The team then systematically knocked out cholesterol biosynthesis enzymes using CRISPR, forcing traffic to back up immediately upstream of whichever conversion step had been blocked. Using lipidomic analysis of sterol extracts from each knockout cell line, they assessed the impact of loss of each enzyme and accumulation of its substrate, identifying key metabolites that impacted levels of HMGCR and SREBP.

The researchers showed that lanosterol down-regulated HMGCR but not SREBP, confirming that lanosterol and not its reduced relative is the key regulator. They also found that other sterol intermediates with reduced double bonds inhibited both HMGCR and SREBP. The authors say that molecules resembling these endogenous regulators could be a new way to control cholesterol levels.

Laurel Oldach

Laurel Oldach is a science writer for the ASBMB.

Join the ASBMB Today mailing list

Sign up to get updates on articles, interviews and events.

Latest in Science

Science highlights or most popular articles

Our internal ecology
Journal News

Our internal ecology

September 29, 2020

According to microbial ecologist Leyuan Li, “We need to start thinking about the gut microbiome like a rainforest.”

A proposal to use CRISPR to prevent opioid overdoses is a useless approach to healthcare
News

A proposal to use CRISPR to prevent opioid overdoses is a useless approach to healthcare

September 27, 2020

Nicholas McCarty of New York University writes that genetically engineering drug users’ brains is short-sighted, reactive and unnecessary.

Lessons from how the polio vaccine
News

Lessons from how the polio vaccine

September 26, 2020

Despite the polio vaccine’s long-term success, manufacturers, government leaders and the nonprofit that funded the vaccine’s development made several missteps.

From the journals: MCP
Journal News

From the journals: MCP

September 25, 2020

How marine iguanas mark their turf. A new way to study Parkinson’s disease. Glycosylation in influenza A. Read about recent papers on these topics in the journal Molecular & Cellular Proteomics.

Gut microbiome shaped by dietary sphingolipids
Journal News

Gut microbiome shaped by dietary sphingolipids

September 22, 2020

A new tracing method described in the Journal of Lipid Research offers clues on how a macronutrient interacts with the microbes that live inside us.

From the journals: JBC
Journal News

From the journals: JBC

September 21, 2020

Proteases that fire up the flu. A sulfate pocket to take out MRSA. Proteins that prompt cancer protrusions. Read about recent papers on these topics and more.